STAT5A is a signal transducer and transcription factor mediating cellular responses to multiple cytokines and growth factors. Mechanistically, STAT5A transduces signals from cytokine receptors, becomes phosphorylated, and translocates to the nucleus where it binds GAS elements to activate target gene transcription 1. STAT5A regulates diverse biological processes including IL-2, IL-4, and IL-15-mediated signaling, T cell development, and lactation-associated gene expression. Notably, STAT5A and STAT5B exhibit distinct, non-redundant roles: while STAT5B regulates T cell development genes (DOCK8, FOXP3, IL2RA), STAT5A uniquely regulates neural development genes (NDRG1, DNAJC6, SSH2) 1. Disease relevance spans multiple cancers with context-dependent effects. High STAT5A expression associates with favorable prognosis in breast, lung, and bladder cancers 2, yet STAT5A promotes epithelial-mesenchymal transition and metastasis in ovarian cancer via a miR-514a-3p/CypA regulatory axis 3. In gastric cancer, m6A methylation-mediated STAT5A upregulation promotes proliferation and migration by repressing KLF4 4. STAT5A is overexpressed in basal cell carcinoma and lymphoid neoplasms 2. In multiple sclerosis, STAT5A downregulation contributes to immune dysregulation 5. Clinically, STAT5A emerges as a potential prognostic biomarker, particularly in breast cancer, and represents a therapeutic target, with selective STAT5 inhibitors (Stafiba) now in development 6.